{
    "ticker": "RVLPQ",
    "name": "Reviva Pharmaceuticals Holdings, Inc.",
    "description": "Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders and other unmet medical needs. Founded in 2010, Reviva's mission is to improve the quality of life for patients by advancing novel treatments that target complex neurological conditions. The company is primarily known for its lead product candidate, RP5063, which is being developed for the treatment of schizophrenia and other CNS disorders. RP5063 is a novel antipsychotic with a unique mechanism of action that aims to provide effective symptom management while minimizing side effects often associated with traditional treatments. Reviva is committed to rigorous clinical research, and its development pipeline includes additional candidates targeting a range of neurological and psychiatric disorders. The company actively collaborates with leading research institutions and healthcare professionals to ensure the efficacy and safety of its drug candidates. Reviva Pharmaceuticals is headquartered in San Jose, California, and continues to seek opportunities that can bring transformative therapies to market, addressing the significant needs within the mental health space.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "San Jose, California, USA",
    "founded": "2010",
    "website": "https://www.revivapharma.com",
    "ceo": "Laxminarayan B. Khedkar",
    "social_media": {
        "twitter": "https://twitter.com/revivapharma",
        "linkedin": "https://www.linkedin.com/company/reviva-pharmaceuticals/"
    },
    "investor_relations": "https://www.reviva.com/investors",
    "key_executives": [
        {
            "name": "Laxminarayan B. Khedkar",
            "position": "CEO"
        },
        {
            "name": "Yogesh C. Khedkar",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "RP5063"
            ]
        }
    ],
    "seo": {
        "meta_title": "Reviva Pharmaceuticals | Innovative CNS Disorder Therapies",
        "meta_description": "Explore Reviva Pharmaceuticals Holdings, Inc., a leader in developing novel treatments for CNS disorders. Learn about our mission, pipeline, and impact on mental health.",
        "keywords": [
            "Reviva Pharmaceuticals",
            "CNS Disorders",
            "Biopharmaceutical",
            "Mental Health",
            "Antipsychotic",
            "RP5063"
        ]
    },
    "faq": [
        {
            "question": "What is Reviva Pharmaceuticals known for?",
            "answer": "Reviva Pharmaceuticals is known for its innovative therapies for central nervous system disorders, particularly its lead candidate RP5063."
        },
        {
            "question": "Who is the CEO of Reviva Pharmaceuticals?",
            "answer": "Laxminarayan B. Khedkar is the CEO of Reviva Pharmaceuticals Holdings, Inc."
        },
        {
            "question": "Where is Reviva Pharmaceuticals headquartered?",
            "answer": "Reviva Pharmaceuticals is headquartered in San Jose, California, USA."
        },
        {
            "question": "What is RP5063?",
            "answer": "RP5063 is Reviva's lead product candidate designed to treat schizophrenia and other CNS disorders."
        },
        {
            "question": "When was Reviva Pharmaceuticals founded?",
            "answer": "Reviva Pharmaceuticals was founded in 2010."
        }
    ],
    "competitors": [
        "ACAD",
        "PRTA",
        "XLRN"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "ABBV"
    ]
}